Table 1 Patient demographics with non-parametric methods for testing whether clinical features and samples of OWT-VAC, Mini-VAC, and Mini-VAC-Instill originate from the same distribution
From: Short-term and long-term outcomes of intrathoracic vacuum therapy of empyema in debilitated patients
Baseline characteristic | Total (n = 43) | OWT-VAC (n = 20) | Mini-VAC (n = 8) | Mini-VAC-Instill (n = 15) | p-value |
|---|---|---|---|---|---|
Age [years], mean (range) | 64 (25–91) | 65 (39–85) | 57 (43–68) | 67 (25–91) | 0.243a |
Sex, n (%) | 0.237c | ||||
Women | 4/43 (9 %) | 1/20 (5 %) | 0/8 (0 %) | 3/15 (20 %) | |
Men | 39/43 (91 %) | 19/20 (95 %) | 8/8 (100 %) | 12/15 (80 %) | |
Multimorbidity | 32/43 (74 %) | 15/20 (75 %) | 7/8 (88 %) | 10/15 (67 %) | 0.534c |
Empyema side, n (%) | 0.039c | ||||
Right | 27/43 (63 %) | 11/20 (55 %) | 3/8 (38 %) | 13/15 (87 %) | |
Left | 16/43 (37 %) | 9/20 (45 %) | 5/8 (62 %) | 2/15 (13 %) | |
Immunosuppression, n (%) | 19/43 (44 %) | 8/20 (40 %) | 4/8 (50 %) | 7/15 (47 %) | 0.851c |
Previous antibiotics, n (%) | 28/43 (65 %) | 11/20 (55 %) | 7/8 (88 %) | 10/15 (67 %) | 0.285c |
Malignancy | 19/43 (44 %) | 11/20 (55 %) | 3/8 (38 %) | 5/15 (33 %) | 0.443c |
Empyema genesis, n (%) | 0.057c | ||||
Primary | 17/43 (40 %) | 4/20 (20 %) | 5/8 (62 %) | 8/15 (53 %) | |
Secondary-postoperative | 26/43 (60 %) | 16/20 (80 %) | 3/8 (38 %) | 7/15 (47 %) | |
ATS empyema stage, n (%) | 0.464c | ||||
Stage II | 37/43 (86 %) | 17/20 (85 %) | 8/8 (100 %) | 12/15 (80 %) | |
Stage III | 6/43 (14 %) | 3/20 (15 %) | 0/8 (0 %) | 3/15 (20 %) | |
Recurrent empyema with previous treatment, n (%) | 28/43 (65 %) | 13/20 (65 %) | 7/8 (88 %) | 8/15 (53 %) | 0.285c |